KDMN
:NASDAQ

Add to watchlist
$8.83
Last updated:09/24/2021
KDMN: NASDAQ
$8.83
Kadmon Holdings Inc

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of c…

P/E ratio
-
vs. 0.00x forward
Stock volatility (Beta)
past 12 months
Become our supporter to unlock all data!
Company results
Qtr
Ann
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
Create free account to unlock
Cashflow
Sum up money going in and out company
Create free account to unlock
Total liabilities
All combined debts and obligations
Create free account to unlock
Stock exposure in ETFs
ETF
Percentage of ETF
Become a premium member and see all 2 ETFs that include this stock
Company profile
CEO
Dr. Harlan W. Waksal
Market capitalization
Small (1.53B)
KDMN price history